关于聚胶新材料股份有限公司 2023 年半年度证券与衍生品投资情况的核查意见 国泰君安证券股份有限公司（以下简称"保荐机构"）作为聚胶新材料股份有限 公司（以下简称"聚胶股份"、"公司"）首次公开发行股票并在创业板上市的保荐机 构，根据《证券发行上市保荐业务管理办法》《深圳证券交易所创业板股票上市规 则》《深圳证券交易所创业板上市公司自律监管指南第 1 号——业务办理》《深圳证 券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》《深圳证券 交易所上市公司自律监管指引第 13 号——保荐业务》等有关规定，对聚胶股份 2023 年半年度证券与衍生品投资情况进行了核查，核查情况及核查意见如下： 国泰君安证券股份有限公司 一、证券与衍生品投资审议批准情况 随着公司海外市场的不断拓展，公司及子公司在日常经营过程中涉及到的外币 业务规模逐渐扩大，持有的外汇资产及外汇负债数量有所上升。为进一步满足公司 及子公司开展外币业务时控制汇率风险的需要，避免外汇市场的大幅波动对公司业 绩造成不良影响，提高外汇资金的使用效率，锁定汇兑成本，公司于 2022 年 3 月 28 日召开第一届董事会第八次会议、第一届监事会第 ...

（一）实际募集资金金额和资金到账时间 证券代码：301283 证券简称：聚胶股份 公告编号：2023-042 聚胶新材料股份有限公司 董事会关于 2023 年半年度 募集资金存放与使用情况的专项报告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 根据中国证券监督管理委员会《上市公司监管指引第 2 号——上市公司募集 资金管理和使用的监管要求（2022 年修订）》（证监会公告〔2022〕15 号）和 《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》 （深证上〔2022〕14 号）等相关规定，聚胶新材料股份有限公司（以下简称 "公 司"）董事会编制的 2023 年半年度募集资金存放与使用情况的专项报告如下： 一、募集资金基本情况 经中国证券监督管理委员会《关于同意聚胶新材料股份有限公司首次公开发 行股票注册的批复》（证监许可〔2022〕952 号）同意注册，并经深圳证券交易 所同意，公司首次公开发行人民币普通股（A 股）2,000 万股，每股发行价为人 民币 52.69 元，募集资金总额为 105,380.00 万元，扣除相关发行费用 ...

证券代码：301283 证券简称：聚胶股份 公告编号：2023-040 聚胶新材料股份有限公司 关于控股股东及其他关联方占用资金情况专项公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 聚胶新材料股份有限公司（以下简称"公司"）根据《深圳证券交易所上市公 司自律监管指引第 2 号——创业板上市公司规范运作》《深圳证券交易所创业板 上市公司自律监管指南第 1 号——业务办理》等有关规定的要求，对 2023 年半 年度控股股东及其他关联方占用公司资金情况进行了自查；公司独立董事亦对 2023 年半年度控股股东及其他关联方占用公司资金情况进行了核查，并发表了 独立意见。具体内容公告如下： 一、2023 年半年度控股股东及其他关联方占用资金情况说明 2023 年半年度，公司控股股东及其他关联方不存在违规占用公司资金的情 况，也不存在以前年度发生并累积至 2023 年 6 月 30 日的控股股东及其他关联方 违规占用公司资金的情况。具体情况详见附件《非经营性资金占用及其他关联资 金往来情况汇总表》（以下简称"汇总表"）。 为了更好地理解公司 2023 年半年度控股股 ...

聚胶新材料股份有限公司 投资者关系活动记录表 证券简称：聚胶股份 证券代码：301283 编号：2023-004 | --- | --- | --- | |----------------|------------------------------|----------------------------------------------------------| | | 特定对象调研 | □分析师会议 | | 投资者关系活动 | □媒体采访 □业绩说明会 | | | 类别 | | | | | □新闻发布会 □路演活动 | | | | 现场参观 □其他 | | | 形式 | 现场 | □网上 □电话会议 | | | | 华泰证券黄伟明、华泰证券张雄、华泰证券孙丹阳、 | | | | 东方证券韩冰、银河基金盛兆、玄元投资陈迪安、 | | 参与单位名称及 | | 彤源投资陆凤鸣、平安基金王修宝、中金李熹凌、 | | 人员姓名 | | 晓鹰投资邓昊程、晓鹰资产查民、东北证券莫然、 | | | | 国联证券申起昊、鹏华基金王曦炜、宝盈基金谢圳棠、 | | | | 长城基金李金洪、惠升基金巢前、中庚基金孙伟 | | ...

解一下: 一、波兰工厂目前已经试生产，有海外客户订单了吗？ 或已经开始按订单出货了吗？二、广州的工厂目前产量利用率是 多少？公司的产品库存平均周转是多少周？三、公司的股价一直 在发行价之下，二级市场投资者损失惨重，公司和管理层会准备 回购股份吗？四、根据目前的订单，今年上半年相比去年订单增 长多少，生产和营运成本同比有下降吗？ （1）波兰工厂于 2022 年 11 月正式投产后开始满足欧洲、 北美以及中东地区客户的订单需求并按订单要求出货。 （2）公司目前整体产能利用率为 80%左右，公司产品库存 平均周转一般在 2-3 周。 聚胶新材料股份有限公司 投资者关系活动记录表 证券简称：聚胶股份 证券代码：301283 编号：2023-003 | 投资者关系活动 | □特定对象调研 □分析师会议 | | --- | --- | | | □媒体采访 业绩说明会 | | 类别 | □新闻发布会 □路演活动 | | | □现场参观 □其他 | | 形式 | □现场 网上 □电话会议 | | 参与单位名称及 | 参与聚胶股份 2022 年度集体业绩说明会的广大投资者 | | 人员姓名 | | | 时间 | 年 月 日 ...

证券代码：301283 证券简称：聚胶股份 公告编号：2023-023 聚胶新材料股份有限公司 关于举行 2022 年度业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 聚胶新材料股份有限公司（以下简称"公司"）已于2023年4月25日在巨潮资 讯网(www.cninfo.com.cn)披露了《2022年年度报告》及《2022年年度报告摘要》。 为便于广大投资者进一步了解公司2022年度经营情况，公司定于2023年5月29日 以网络远程的方式举行2022年度业绩说明会。现将有关事项公告如下： 本次说明会将采用网络远程方式举行，投资者可登陆全景网"投资者关系互 动平台"（https://ir.p5w.net）参与本次年度业绩说明会。 三、出席人员 出席本次年度业绩说明会的人员有：公司董事长、总经理陈曙光先生，董事 会秘书、财务负责人师恩成先生，独立董事葛光锐女士，保荐代表人肖峥祥先生 （如有特殊情况，参会人员可能进行调整）。 四、问题征集 为充分尊重投资者、提升交流的针对性，现就公司2022年度业绩说明会提前 向投资者公开征集问题，广泛听取投资者 ...

Financial Performance - The company's operating revenue for 2022 was approximately ¥1.35 billion, representing a 28.18% increase compared to ¥1.05 billion in 2021[20]. - The net profit attributable to shareholders for 2022 was approximately ¥87.29 million, a 59.37% increase from ¥54.77 million in 2021[20]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was approximately ¥77.77 million, up 48.79% from ¥52.27 million in 2021[20]. - The total assets at the end of 2022 reached approximately ¥1.68 billion, a 163.56% increase from ¥637.18 million at the end of 2021[20]. - The net assets attributable to shareholders at the end of 2022 were approximately ¥1.41 billion, a 297.71% increase from ¥355.46 million at the end of 2021[20]. - The basic earnings per share for 2022 was ¥1.3094, reflecting a 43.43% increase from ¥0.9129 in 2021[20]. - The cash flow from operating activities for 2022 was negative at approximately -¥72.89 million, a significant decrease from -¥8.41 million in 2021[20]. - The company reported quarterly revenues of ¥310.26 million, ¥320.86 million, ¥350.12 million, and ¥369.51 million for Q1 to Q4 respectively in 2022[22]. - The weighted average return on equity for 2022 was 12.05%, down from 16.05% in 2021[20]. - The company reported a total non-operating income of 9,523,505.54 in 2022, a significant increase of 279.5% compared to 2,506,075.75 in 2021[26]. Risk Management - The company faces risks including slowing growth, raw material price fluctuations, and overseas operational risks[4]. - The management highlighted the importance of recognizing the differences between plans, forecasts, and commitments, urging investors to be aware of investment risks[4]. - The report emphasizes the need for investors to pay attention to potential risks in future development strategies[4]. - The company has outlined its future development outlook, which includes addressing various risk factors[4]. - The company is closely monitoring exchange rate fluctuations, particularly with the euro and US dollar, to minimize the impact on its foreign currency sales revenue[129]. - The company is implementing measures to mitigate risks related to the loss of technical personnel and the potential for technology leakage, which could impact its innovation capabilities[128]. Corporate Governance - The board of directors confirmed the accuracy and completeness of the financial report, with key personnel taking individual and joint legal responsibility[3]. - The company has established a governance structure consisting of the shareholders' meeting, board of directors, supervisory board, and senior management, ensuring clear responsibilities and effective operations[133]. - The company has revised 16 governance documents, including the Articles of Association and various meeting rules, to enhance governance and operational transparency[134]. - The company has established a performance evaluation and incentive mechanism linking compensation to company performance and individual contributions[144]. - The company strictly adheres to information disclosure regulations, ensuring timely and accurate information is available to all investors[142]. - The company has set up a dedicated investor relations department to facilitate communication and feedback from investors through multiple channels[143]. - The company has not experienced any significant discrepancies between its governance practices and the regulations set forth by the China Securities Regulatory Commission[144]. Research and Development - The company invested 54.33 million yuan in R&D, a 64.85% increase from the previous year, constituting 4.02% of total revenue[58]. - The company has developed 21 patent technologies, including 3 invention patents, and has over 160 product formulas[52]. - The company is developing a high-performance hot melt adhesive based on domestic raw materials, aiming to enhance market competitiveness[77]. - A biodegradable hot melt adhesive is under development to improve sustainability capabilities[77]. - The company plans to develop a high-end medical hot melt adhesive to meet the demands of the domestic medical market[77]. - The number of R&D personnel increased by 8.82% from 34 in 2021 to 37 in 2022, while the proportion of R&D personnel in the total workforce decreased from 13.65% to 10.63%[79]. Market Expansion - The company plans to continue expanding its market presence and investing in new product development to drive future growth[20]. - The company has established itself as one of the top four suppliers of medical hot melt adhesives in the industry, successfully replacing imports and becoming the largest domestic producer[37]. - The market for medical hot melt adhesives is expected to continue growing, driven by increasing hygiene awareness and a growing aging population, particularly in developed countries[33]. - The company has entered the qualified supplier system of the top ten global hygiene product manufacturers, although its market share remains low, especially in North America, Japan, and Western Europe[36]. - The company is actively expanding its overseas market presence, focusing on regions such as Asia, Europe, and Africa[67]. - The company aims to expand its market share by focusing on the top ten global sanitary product manufacturers and increasing overseas market penetration[115]. Financial Management - The company reported a total fundraising amount of RMB 105,380 million, with a net amount of RMB 96,220.43 million after deducting underwriting and related fees[99]. - The total unused raised funds amounted to RMB 61,017.43 million, with RMB 4,017.43 million in a special account and RMB 57,000 million in cash management[100]. - The company achieved foreign exchange gains during the reporting period due to the appreciation of the US dollar[95]. - The company does not engage in speculative derivative investments, focusing solely on hedging to manage foreign exchange risks[97]. - The company has established a financial derivatives management system to regulate trading behaviors and control associated risks[95]. - The company reported a total investment of ¥1,695,731,134.37 for the reporting period, a substantial increase of 286.14% compared to the previous year[88]. Employee Management - The total number of employees at the end of the reporting period was 348, with 270 in the parent company and 78 in major subsidiaries[177]. - The company has a competitive and fair compensation policy, with a focus on attracting and retaining talent, including basic salary, performance bonuses, and overtime pay[178]. - The company emphasizes continuous improvement in its compensation system to enhance employee satisfaction and alignment with corporate goals[178]. - The company has established a comprehensive training system, including new employee training and annual training, to enhance employee skills and work efficiency[179]. - The company reported zero retired employees requiring financial support, indicating a focus on maintaining a stable workforce[177]. Dividend Policy - The proposed cash dividend for 2022 is CNY 40,000,000.00, which corresponds to CNY 5.00 per 10 shares, representing 100% of the total distributable profit[191][194]. - The company aims to distribute at least 30% of the average distributable profit over the last three years as cash dividends, with a minimum of 80% for mature companies without major capital expenditure plans[185]. - The company’s profit distribution policy prioritizes cash dividends, ensuring that cash flow remains sufficient for normal operations after distribution[183]. - The board of directors emphasizes the importance of communication with minority shareholders during the dividend distribution process[188]. - The company has established a comprehensive decision-making mechanism for profit distribution, requiring independent board approval before submission to the shareholders' meeting[189].

Financial Performance - The company's revenue for Q1 2023 was ¥385,036,134.30, representing a 24.10% increase compared to ¥310,255,627.92 in the same period last year[5] - Net profit attributable to shareholders was ¥15,228,818.51, up 24.65% from ¥12,217,547.04 year-on-year[5] - Total operating revenue for Q1 2023 reached ¥385,036,134.30, an increase of 24.1% compared to ¥310,255,627.92 in the same period last year[23] - Net profit for Q1 2023 was ¥15,136,262.77, representing a 25.8% increase from ¥12,058,708.64 in Q1 2022[24] - The total comprehensive income for the first quarter of 2023 was CNY 18,525,094.27, compared to CNY 9,148,292.19 in the same period last year, representing an increase of approximately 102.5%[25] Cash Flow - The net cash flow from operating activities was -¥43,987,583.72, a significant decrease of 1,195.80% compared to ¥4,014,193.73 in the previous year[5] - Cash inflow from operating activities was CNY 353,661,141.34, an increase from CNY 295,939,916.23 in the previous year, marking a growth of approximately 19.5%[27] - The company reported a cash outflow of CNY 397,648,725.06 from operating activities, compared to CNY 291,925,722.50 in the previous year, indicating an increase of approximately 36.2%[28] - Cash inflow from investment activities totaled CNY 933,698,575.15, significantly higher than CNY 89,699,801.35 in the previous year, indicating a substantial increase of approximately 938.5%[28] - The net cash flow from investment activities was CNY 55,944,191.29, compared to a negative CNY 8,695,442.39 in the previous year, showing a turnaround in performance[28] Assets and Liabilities - Total assets at the end of Q1 2023 were ¥1,645,274,271.07, down 2.03% from ¥1,679,355,460.40 at the end of the previous year[5] - Total current liabilities decreased to ¥205,420,265.67 from ¥256,543,279.17 at the beginning of the year, reflecting a reduction of 20%[21] - The company's cash and cash equivalents increased to ¥198,525,211.24 from ¥189,108,260.06 at the beginning of the year, showing a growth of 7.5%[20] - Inventory at the end of Q1 2023 was ¥200,089,014.62, down from ¥206,776,250.09 at the beginning of the year, indicating a decrease of 3.2%[20] - The company's equity attributable to shareholders increased to ¥1,432,314,962.27 from ¥1,413,697,312.26 at the beginning of the year, reflecting a growth of 1.3%[21] Expenses - Basic and diluted earnings per share decreased by 6.48% to ¥0.1904 from ¥0.2036 in the same period last year[5] - Research and development expenses increased by 92.67% to ¥14,916,032.23 from ¥7,741,633.21 year-on-year, indicating a focus on innovation[9] - Management expenses rose by 116.21% to ¥9,576,631.88, primarily due to increased salary and travel costs[9] - Total operating costs for Q1 2023 were ¥367,337,706.03, up 24.1% from ¥295,956,640.43 in Q1 2022[23] Shareholder Information - The total number of common shareholders at the end of the reporting period was 6,075[11] - The largest shareholder, Guangzhou JuJiao Enterprise Management Co., Ltd., holds 16.20% of shares, totaling 12,956,907 shares[11] - The top ten shareholders collectively hold a significant portion of shares, with the second-largest shareholder holding 9.93%[11] Innovation and Development - The company has achieved a biodegradable rate of 92.67% for a specific product, up from 77.68% previously[15] - The company is focused on continuous innovation to enhance its product offerings and market competitiveness[15] - The company has established a comprehensive R&D system to maintain technological leadership in the industry[15] - The company has made progress in customer and product certification for its Poland factory as part of its expansion strategy[17] - The company has implemented an ERP system and an electronic bidding system to optimize procurement processes and reduce risks[16] Government Support - The company received government subsidies amounting to ¥1,593,750.68, a 114.75% increase from ¥742,130.75 in the previous year[9] Reporting and Audit - The company did not undergo an audit for the first quarter report[30] - The report was released on April 25, 2023, by the board of directors of the company[30]